atenolol has been researched along with Albuminuria in 28 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 9.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 9.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 9.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 9.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria." | 7.68 | Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991) |
| "With ramipril treatment urinary albumin creatinine ratio (14." | 6.68 | Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| " atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6-24 months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 24 months, and predicted the composite endpoint (CEP) of cardiovascular death, nonfatal myocardial infarction (MI) or stroke occurring after 24 months (CEP = 630 events)." | 5.20 | Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Mancia, G; Okin, PM; Olsen, MH; Rothwell, PM; Vishram, JK; Wachtell, K, 2015) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| "The CARDHIAC (CARduran en pacientes Diabéticos con HIpertensi'on Arterial no Controlada) trial examined the effects of doxazosin gastrointestinal therapeutic system (GITS) and atenolol on 3 separate measures of target-organ damage--left ventricular mass index (LVMI), carotid intima media thickness (IMT), and urinary albumin excretion (UAE)--in patients with type 2 diabetes mellitus and hypertension." | 5.13 | Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. ( Barrios, V; Calderon, A; Echarri, R; Escobar, C; Tomás, JP, 2008) |
| "Our current aims were to investigate whether 1) baseline urinary albumin-to-creatinine ratio (UACR) predicted cardiovascular outcomes, 2) changes in UACR differed between treatments, 3) benefits of losartan were related to its influence on UACR, and 4) reduction in albuminuria reduced cardiovascular events." | 5.12 | Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Ibsen, H; Lindholm, LH; Lyle, PA; Mogensen, CE; Olsen, MH; Snapinn, SM; Wachtell, K; Wan, Y, 2006) |
| "To examine a possible relationship between baseline albuminuria and effect of losartan versus atenolol on cardiovascular (CV) events in hypertensive patients with left ventricular hypertrophy, the effect of losartan versus atenolol on albuminuria, and whether the benefits of losartan versus atenolol could be explained by influence of losartan on albuminuria." | 5.11 | Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2004) |
| "8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study." | 5.11 | Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. ( Borch-Johnsen, K; Dahlöf, B; de Faire, U; Devereux, RB; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Lederballe-Pedersen, O; Lindholm, LH; Mogensen, CE; Nieminen, MS; Olsen, MH; Omvik, P; Oparil, S; Wachtell, K; Wan, Y, 2005) |
| "Given a similar level of arterial pressure control, both lisinopril and diltiazem slow progression of diabetic renal disease and reduce albuminuria to a greater extent than does the combination of a loop diuretic and beta-adrenoreceptor antagonist." | 5.07 | Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. ( Bakris, GL; Sadler, R; Slataper, R; Vicknair, N, 1993) |
| "We prospectively measured UAE prior to and 4 and 8 weeks after treatment with enalapril, nitrendipine, atenolol, or a diuretic in 48 patients with essential hypertension and microalbuminuria." | 5.07 | Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs. ( Baldari, G; Bianchi, S; Bigazzi, R; Campese, VM, 1992) |
| "In 9193 hypertensive patients included in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, we measured urine albumin/creatinine ratio (UACR), LV hypertrophy by electrocardiography, serum high-density lipoprotein (HDL) cholesterol, and blood pressure after 2 weeks of placebo treatment and yearly during 5 years of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.76 | Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study. ( Dahlöf, B; Devereux, RB; Kjeldsen, SE; Okin, PM; Olsen, MH; Søraas, CL; Tønnessen, T; Wachtell, K, 2010) |
| "In 6679 hypertensive patients included in the LIFE study, we measured UACR, left ventricular hypertrophy by electrocardiography, serum cholesterol, plasma glucose and blood pressure after 2 weeks of placebo treatment and again after 1 year of anti-hypertensive treatment with either an atenolol- or a losartan-based regimen." | 3.73 | Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Oikarinen, L; Okin, PM; Olsen, MH; Wachtell, K, 2006) |
| "Fifty patients with stable slight and moderate uncomplicated essential hypertension, treated by ramipril, atenolol, or isradipine, were examined." | 3.70 | [Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension]. ( Betekhtina, VA; Rakov, SS, 2000) |
| "Nine patients with Type I diabetes mellitus, diastolic blood pressure of 90 to 100 mmHg and persistent microalbuminuria of greater than or equal to 30 micrograms/min were treated with 50 to 100 mg atenolol daily for 3 years in an uncontrolled pilot study to assess the effect of long-term reduction of blood pressure on microalbuminuria." | 3.68 | Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients. ( Davies, JA; Stickland, M; Tindall, H; Urquhart, S, 1991) |
| "1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8." | 2.69 | Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. ( , 1998) |
| "With ramipril treatment urinary albumin creatinine ratio (14." | 2.68 | Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. ( Hoffmann, W; Hopmeier, P; Schernthaner, G; Schnack, C, 1996) |
| "The progression of diabetic nephropathy can be positively influenced by maintaining a low blood pressure level." | 2.67 | Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. ( Berden, JH; de Nobel, E; Elving, LD; van Lier, HJ; Wetzels, JF, 1994) |
| "Diabetic nephropathy is characterized by hypertension and a relentless decline in kidney function." | 2.67 | Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. ( Gall, MA; Nielsen, FS; Parving, HH; Rossing, P; Skøtt, P; Smidt, UM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.14) | 18.7374 |
| 1990's | 12 (42.86) | 18.2507 |
| 2000's | 11 (39.29) | 29.6817 |
| 2010's | 3 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vishram, JK | 1 |
| Dahlöf, B | 8 |
| Devereux, RB | 7 |
| Ibsen, H | 7 |
| Kjeldsen, SE | 6 |
| Lindholm, LH | 6 |
| Mancia, G | 1 |
| Okin, PM | 4 |
| Rothwell, PM | 1 |
| Wachtell, K | 8 |
| Olsen, MH | 8 |
| Søraas, CL | 1 |
| Tønnessen, T | 1 |
| Matsui, Y | 1 |
| Eguchi, K | 1 |
| Shibasaki, S | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Shimada, K | 1 |
| Kario, K | 1 |
| Borch-Johnsen, K | 4 |
| Mogensen, CE | 3 |
| de Faire, U | 2 |
| Fyhrquist, F | 2 |
| Julius, S | 3 |
| Lederballe-Pedersen, O | 2 |
| Nieminen, MS | 4 |
| Omvik, P | 2 |
| Oparil, S | 2 |
| Wan, Y | 3 |
| Bella, JN | 1 |
| Palmieri, V | 1 |
| Gerdts, E | 1 |
| Smith, G | 1 |
| Snapinn, SM | 1 |
| Lyle, PA | 1 |
| Oikarinen, L | 2 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Viitasalo, M | 1 |
| Toivonen, L | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Tomás, JP | 1 |
| Calderon, A | 1 |
| Echarri, R | 1 |
| Elving, LD | 1 |
| Wetzels, JF | 1 |
| van Lier, HJ | 1 |
| de Nobel, E | 1 |
| Berden, JH | 1 |
| Nielsen, FS | 2 |
| Rossing, P | 2 |
| Gall, MA | 2 |
| Skøtt, P | 2 |
| Smidt, UM | 2 |
| Parving, HH | 2 |
| Slataper, R | 1 |
| Vicknair, N | 1 |
| Sadler, R | 1 |
| Bakris, GL | 1 |
| Rangemark, C | 1 |
| Lind, H | 1 |
| Lindholm, L | 1 |
| Hedner, T | 2 |
| Samuelsson, O | 2 |
| Schnack, C | 1 |
| Hoffmann, W | 1 |
| Hopmeier, P | 1 |
| Schernthaner, G | 1 |
| Kribben, A | 1 |
| Anlauf, M | 1 |
| Distler, A | 1 |
| Gärtner, H | 1 |
| Holzgreve, H | 1 |
| Michaelis, J | 1 |
| Röcker, L | 1 |
| Schäfers, R | 1 |
| Philipp, U | 1 |
| Wellek, S | 1 |
| Philipp, T | 1 |
| Rakov, SS | 1 |
| Betekhtina, VA | 1 |
| Redon, J | 1 |
| Rovira, E | 1 |
| Miralles, A | 1 |
| Julve, R | 1 |
| Pascual, JM | 1 |
| Stornello, M | 1 |
| Valvo, EV | 1 |
| Scapellato, L | 1 |
| Ljungman, S | 1 |
| Herlitz, H | 1 |
| Widgren, B | 1 |
| Pennert, K | 1 |
| Bianchi, S | 1 |
| Bigazzi, R | 1 |
| Baldari, G | 1 |
| Campese, VM | 1 |
| Tindall, H | 2 |
| Urquhart, S | 1 |
| Stickland, M | 1 |
| Davies, JA | 2 |
| Hopper, AH | 1 |
| Christensen, CK | 1 |
| Krusell, LR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-blind,Placebo-controlled Multicentre Trial With 4 Parallel Groups[NCT00328601] | Phase 3 | 170 participants | Interventional | 2005-02-28 | Completed | ||
| The Glooko Diabetes Mobile Monitoring and Management Advantage Study[NCT02974816] | 197 participants (Actual) | Interventional | 2017-05-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 trials available for atenolol and Albuminuria
| Article | Year |
|---|---|
Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascu | 2015 |
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Diuretics; | 2004 |
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2005 |
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Topics: Aged; Albuminuria; Antihypertensive Agents; Aortic Valve; Atenolol; Cardiovascular Diseases; Double- | 2005 |
Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cr | 2006 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.
Topics: Age Factors; Albuminuria; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Carotid Artery, | 2008 |
Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.
Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Captopril; Diabetes Mellitus, Type 1; Diabetic Nephrop | 1994 |
Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Albuminuria; Apolipoproteins; Apoprotein(a); Atenolol; Blood Pressure; Circadian Rhythm; Diabetes Me | 1994 |
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease.
Topics: Albuminuria; Antihypertensive Agents; Atenolol; Diabetic Nephropathies; Diltiazem; Dipeptides; Furos | 1993 |
Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cross- | 1996 |
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.
Topics: Adrenergic beta-Antagonists; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 1996 |
Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Ateno | 1997 |
Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters. The HANE Trial Research Group.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Ant | 1997 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1998 |
Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2002 |
Persistent albuminuria in normotensive non-insulin-dependent (type II) diabetic patients: comparative effects of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers.
Topics: Adult; Aged; Albuminuria; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 1992 |
A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blo | 1992 |
Microalbuminuria in patients with essential hypertension: effects of several antihypertensive drugs.
Topics: Adult; Aged; Albuminuria; Analysis of Variance; Antihypertensive Agents; Atenolol; Creatinine; Diure | 1992 |
Acute and long-term effect of antihypertensive treatment on exercise induced microalbuminuria in essential hypertension.
Topics: Adult; Albuminuria; Atenolol; beta 2-Microglobulin; Blood Pressure; Clinical Trials as Topic; Double | 1987 |
8 other studies available for atenolol and Albuminuria
| Article | Year |
|---|---|
Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Topics: Aged; Albuminuria; Angina Pectoris; Antihypertensive Agents; Atenolol; Blood Pressure; Cholesterol, | 2010 |
Impact of arterial stiffness reduction on urinary albumin excretion during antihypertensive treatment: the Japan morning Surge-1 study.
Topics: Aged; Albuminuria; Ankle Brachial Index; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Bra | 2010 |
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Cholesterol; Cr | 2006 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
[Kidney protection leads to heart protection, too].
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2006 |
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Apolipoproteins; Atenolol; Biomarkers; Complement | 2000 |
Treatment with atenolol prevents progression of microalbuminuria in type I diabetic patients.
Topics: Adult; Albuminuria; Atenolol; Blood Pressure; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephro | 1991 |
The course of incipient diabetic nephropathy.
Topics: Adult; Albuminuria; Atenolol; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Middle Aged | 1986 |